Skip to main content

Table 4 Calculated doses to the public for each cycle of 177Lu-PSMA-617 therapy for different time points of discharge of the patient from the hospital using different assumptions for the effective half-life

From: External radiation exposure, excretion, and effective half-life in 177Lu-PSMA-targeted therapies

Estimated dose to the public [μSv] after 1 cycle of 177Lu-PSMA-617 therapy
Time point of discharge 24 h p. i.a 48 h p. i. 72 h p. i.b
Type of half-life T 1/2ind T 1/2phys T 1/2max T 1/2ind T 1/2phys T 1/2max T 1/2ind T 1/2phys T 1/2max
Mean 99 396 208 71 263 139 50 200 105
Std. Dev. 58 131 69 51 100 53 35 76 40
Min 25 142 75 13 93 49 17 93 49
Max 318 779 410 264 560 294 204 443 233
  1. aFor the effective individual half-life, the value from the 48-h measurement point was used (see the “Results” section)
  2. bThese data are only available for 25 patients (cohort of Department 2)